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The question of whether Epstein–Barr nuclear antigen 1 (EBNA1) includes cytotoxic T lymphocyte (CTL) epitopes has
generated considerable scientific interest, primarily due to its important implications for the overall biology of Epstein–Barr
virus (EBV). Earlier studies have suggested that EBV-associated malignancies that express only EBNA1 escape virus-specific
immune surveillance since this antigen is not a target for CTL recognition. In the present report we have used a modified
protocol to demonstrate that EBNA1 includes sequences which can be recognized by both polyclonal and clonal CTLs.
CD4/ CTL clones were isolated from a healthy, seropositive donor that recognized the peptide epitope TSLYNLRRGTALA
from EBNA1 in association with HLA DR1. Interestingly, these CTLs are unable to lyse EBV-infected B cells suggesting that
EBNA1 may not be endogenously processed and/or presented to the host CTL response. Despite recent suggestions that
glycine–alanine repeat sequences within EBNA1 can inhibit endogenous processing, target cells infected with recombinant
vaccinia vectors encoding truncated EBNA1 proteins, without these repeat sequences, were not recognized by this CTL
clone. Thus it seems that the presence of glycine–alanine repeats is not responsible for inhibiting the processing of the
class II-restricted epitope defined in this study. These results substantiate the view that EBV-infected normal and malignant
cells, where viral gene expression is limited to EBNA1, can resist CTL-mediated immune surveillance in vivo. q 1995 Academic
Press, Inc.
recombinant vaccinia encoding each of the EBV nuclearEpstein–Barr virus (EBV) is a member of the human
antigens (EBNA) and latent membrane proteins (LMPs),herpesvirus family that maintains a life-long latent asso-
numerous CTL epitopes were mapped within EBNA2-6ciation with B lymphocytes and a permissive association
and LMP, while no CTL response was detected againstwith stratified epithelium in the oropharynx (1, 2). Two
EBNA1.types of EBV (1 and 2, also referred to as A and B) are
The question of whether EBNA1 includes CTL epitopesrecognized that show DNA sequence divergence within
has generated considerable scientific interest, primarilythe BAM H1 WYH and E regions of the genome (3, 4).
due to its important implications for the overall biology ofThere is now convincing evidence that EBV-specific
EBV. First, it has been proposed that the EBV-associatedmemory CD8/ and CD4/ cytotoxic T lymphocytes (CTL)
tumor, Burkitt’s lymphoma (BL), escapes virus-specificare responsible for controlling the level of EBV-positive
immune surveillance by restricting latent gene expres-B lymphocytes which all healthy, seropositive individuals
sion to EBNA1 (11). This view is reinforced by earliercarry for life following primary infection with the virus (5–
studies which showed that BL patients retain detectable7). Previous studies have defined the relative distribution
EBV-specific T cell surveillance, indicating that CTL dys-of CTL epitopes within EBV latent proteins recognized
function is an unlikely cause of the outgrowth of theseby T cells clones from healthy immune individuals ex-
EBV-infected tumors in vivo (12). Second, it has recentlypressing an array of MHC class I alleles (8–10). Using
been shown that EBV-infected B cells, expressing EBNA1
and LMP2a only, are capable of maintaining the latent
viral infection in vivo (13). Third, an earlier study carried1 A part of this work was presented at the CIBA Foundation Sympo-
sium on Vaccines against Virally Induced Cancers; March 15–17, 1994. out by Trivedi and colleagues clearly showed that mam-
2 These two authors contributed equally in this work and their order
mary carcinoma cells transfected with the EBNA1 geneshould be considered arbitrary.
were not rejected by histocompatible mice, whereas3 To whom reprint requests should be addressed. Fax: 61-7-362 0106;
E-mail: rajivK@qimr.edu.au. LMP-transfected cells were regularly rejected (14). Thus
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ratio of 20:1). These polyclonal CTLs were tested against
autologous phytohemagglutinin (PHA) blasts presensi-
tized with an overlapping net of EBNA1 peptides (15-mer
overlapping by 10 amino acids) as described earlier (15).
Polyclonal CTLs from donors LC and DM, stimulated
with autologous LCLs, recognized four different peptides
from EBNA1. CTLs from donor LC showed reactivity
against peptide 49 (RRGTALAIPQCRLTP), while CTLs
from donor DM recognized autologous PHA blasts in
the presence of peptides 30 (EPDVPPGAIEQGPAD), 47
(GGSKTSLYNLRRGTA), and 48 (SLYNLRRGTALAIPQ)
(Figs. 1a and 1b). In contrast, CTLs from donors CM and
NB showed no significant reactivity against any of the
EBNA1 peptides (data not shown). These experiments
were repeated with two different blood samples and con-
sistently the same set of peptides was recognized by
CTLs from donors DM and LC.
To confirm the data obtained with polyclonal effectors,
CTL clones were generated (16) from donors DM and
LC by seeding UM cells or purified CD4/ T cells, after
stimulation with either autologous LCLs or EBNA1 pep-
tides (peptides 30, 47, and 48 for donor DM and peptide
49 for donor LC). CD4/ T cells were purified from fresh
UM cells using a Lymphokwik reagent (One Lambda Inc.,
CA). Colonies were harvested after 3 days and amplified
in culture with biweekly restimulation with rIL-2 and au-
tologous LCL precoated with EBNA1 peptide(s). Two CTL
clones were isolated from donor DM (referred to as DM2
and DM6) following stimulation with peptide 48 (SLYNLR-
FIG. 1. Identification of CTLs specific for EBNA1 peptides in healthy RGTALAIPQ). Clone DM2 was isolated from UM cells,
seropositive individuals. Polyclonal CTLs from donor DM (a) and LC while DM6 was isolated using purified CD4/ T cells.
(b) were used as effectors to test for reactivity against autologous
These CTL clones showed strong T cell–T cell killingPHA blasts presensitized with overlapping EBNA1 peptides. Results
(17) in the presence of peptides GGSKTSLYNLRRGTAare expressed as percentage specific lysis observed in a standard 5-
hr chromium-release assay. An effector to target ratio of 20:1 was used
in the assay.
it is plausible that some virus-infected B cells maintain
a nonimmunogenic phenotype by down-regulating the
critical latent proteins needed for CTL recognition. The
present study was specifically designed to consider the
possibility of detecting an EBNA1-specific CTL response
in healthy EBV-seropositive individuals, since earlier
studies have essentially drawn their conclusions on the
basis of negative evidence.
Unfractionated mononuclear (UM) cells (106/ml) from
EBV-seropositive donors LC (HLA A1, B8, B18, DR3,
DR11), NB (A2, A24, B7, B35, DR11), CM (HLA A11, A24,
B7, B44, DR1, DR4), and DM (A24, A29, B44, Bw47, DR1,
DR7) were cultivated with irradiated (8000 R) autologous
lymphoblastoid cell lines (LCLs) transformed with the
FIG. 2. MHC restriction analysis for CTL clones. Peptide-coated DMtype 1 EBV isolate, B95.8 (responder to stimulator ratio
PHA blasts were precoated with peptide 48 (SLYNLRRGTALAIPQ; 1of 50:1) in 2-ml culture wells (Linbro) in RPMI 1640/10%
mg/ml) and then exposed to CTL clones (DM2 and DM6) in the presence
FCS. After 7 days, cultures were restimulated with autolo- of anti-class I (W6/32) or anti-class II (L243) antibody (1:20 diluted
gous LCLs and on Day 10 the cells were used as ef- ascites). An effector to target ratio of 5:1 was used in the assay. Data
from one representative experiment of three are shown.fectors in a standard 51Cr-release assay (effector:target
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FIG. 3. Minimalizing the EBNA1 epitope. DM anti-CD40 B cell blasts were presensitized with individual overlapping peptides and then exposed
to CTL clone DM2. The peptide sequence shown in a box was identified as the minimal epitope sequence required for maximal lysis. An effector
to target ratio of 5:1 was used in the assay. Data from one representative experiment of two are shown.
and SLYNLRRGTALAIPQ, suggesting that both these were synthesized and screened for recognition by DM2.
As shown in Fig. 3, 10 different peptides were tested andoverlapping sequences might include an EBNA1 epitope.
No CTL clones specific for EBNA1 peptides were iso- compared for the concentration required for half-maximal
lysis of autologous anti-CD40 B cell blasts. These B celllated from donors LC or DM following stimulation with
peptides 30 and 49. blasts were generated as described previously (18).
Based on this analysis, peptide TSLYNLRRGTALA wasCharacterization (by FACS analysis) revealed that DM2
and DM6 were 99.0% CD3/, CD4/ cells, a phenotype the minimal peptide with maximal activity, inducing half-
maximal lysis at a concentration of 0.069 mg/ml.suggesting that these clones might be MHC class II-
restricted. To examine this possibility, autologous PHA An important aspect of the characterization of the CTL
clone was to determine whether DM2 could recognizeblasts were presensitized with peptide 48 and then ex-
posed to the CTL clones in the presence of anti-class I autologous LCLs transformed with a range of virus
strains. These LCLs were established either spontane-(W6/32) or anti-class II (L243) antibody. As shown in Fig.
2, recognition of peptide 48-coated PHA blasts was ously (19) or by exogenous virus transformation of periph-
eral B cells using type 1 or 2 EBV isolates (16). Surpris-blocked by L243 but was not significantly affected by
W6/32 antibody. This result confirmed that these CTL ingly, no LCLs were recognized by DM2 (Fig. 4). The lack
of CTL recognition by DM2 was not due to any defect inclones are MHC class II-restricted.
To minimalize this CTL epitope, overlapping peptides the expression of MHC class II alleles, since all LCLs
FIG. 4. Recognition of DM LCLs transformed with either type 1 or type 2 EBV isolates by CTL clone DM2. An effector to target ratio of 5:1 was
used in the assay. Data from one representative experiment of four are shown.
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FIG. 5. HLA class II restriction analysis for CTL clone DM2. Allogeneic EBV-transformed LCLs, some sharing an MHC class II antigen with donor
DM, were exposed to the CTL clone DM2 in the absence or presence of TSLYNLRRGTALA peptide. An effector to target ratio of 5:1 was used in
the assay. Data from one representative experiment of two are shown.
were efficiently recognized by the clone if presensitized Indeed, the sequence conforms to the previously pub-
with the TSLYNLRRGTALA peptide. This result suggests lished HLA DR1 binding motif (20).
that LCLs are unable to process and present the EBNA1 To determine whether the lack of CTL lysis of autolo-
CTL epitope endogenously. gous LCLs by CTL clone DM2 was due to insufficient
To define the HLA restriction of the CTL clone DM2, levels of EBNA1 expressed in these cells, DM/B95.8
a panel of allogeneic LCLs, some sharing an MHC class LCLs and DM CD40 B cell blasts were infected with
II allele with donor DM, was presensitized with TSLYNL- recombinant vaccinia constructs encoding the full-length
RRGTALA and tested in a standard 51Cr-release assay. EBNA1 gene (Vacc.EBNA1) and vaccinia encoding T7
As shown in Fig. 5, peptide-sensitized LCLs from RNA polymerase (Vacc.T7) (8). Despite high levels of
DR1/ve donors, but not DR10ve donors, were recog- EBNA1 expression in these cells as determined by immu-
nized by CTL clone DM2. These results suggest that noblotting (data not shown), no lysis was seen in the
peptide TSLYNLRRGTALA is restricted through HLA DR1. presence of CTL clone DM2 (Fig. 6). These results con-
firm that, although EBNA1 includes a CTL epitope, this
epitope is not processed and presented endogenously
by EBV-infected cells.
Levitskaya and colleagues have recently demon-
strated that repeat sequences of glycine–alanine within
EBNA1 can inhibit presentation of class I epitopes (21).
To explore the possibility that the lack of endogenous
processing of the TSLYNLRRGTALA epitope relates to
the presence of these repeat sequences, DM target cells
were infected with two recombinant vaccinia vectors
(Vacc.E1DGA and E1DCGA). Each of these constructs
encodes a truncated EBNA1 protein without the glycine–
alanine repeats but including this epitope (P. M. Steige-
wald-Mullen and M. G. Kurilla, submitted for publication).
Interestingly, target cells expressing these proteins were
FIG. 6. Functional analysis of CTL clone DM2 using autologous LCLs
not recognized by CTL clone DM2 (Fig. 6). Thus it seemsor CD40 B cells infected with recombinant vaccinia expressing full-
that the presence of glycine–alanine repeats is not re-length EBNA1 (Vacc.EBNA1), truncated EBNA1 proteins with glycine–
alanine repeat sequences deleted (Vacc.E1DGA and Vacc.E1DCGA), sponsible for inhibiting the processing of the class II-
or with the nuclear localization signal sequence deleted (Vacc.E1DSS), restricted epitope defined in this study. Another possible
as target cells. TSLYNLRRGTALA peptide-coated LCLs and CD40 B reason for the inability of infected cells to endogenouslycells were used as controls. An effector to target ratio of 5:1 was used
process this epitope is that EBNA1 localizes to the nu-in the assay. Data from one representative experiment of four are
shown. cleus, thus limiting class II presentation. However, this
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